Neuroendocrine Cancer of the Prostate

Abstract

Neuroendocrine cancer of the prostate is considered to be a rare entity with bad prognosis and limited therapeutic options. We performed a prospective analysis of the patients treated in our hospital for prostate cancer between 1st January 2015 and 31rd December 2018. Neuroendocrine phenomena were tested by immunohistochemistry and laboratory chemistry on the request of the clinicians in the cases when a positive diagnosis was suspected. Clinical tableaux of high suspicion of neuroendocrine cancer included radiological progression of a metastatic disease without PSA rise, relatively extended metastatic disease associated to a low PSA, disease with non-pulmonary visceral metastases. 10 patients were diagnosed with neuroendocrine tumour out of 521 prostate cancers. Half of the patients had a survival over a year. 3 patients received 3 lines of efficacious palliative chemotherapy. 1 patient underwent prostatectomy after neoadjuvant chemotherapy for a localised disease. The incidence of neuroendocrine tumours among prostate cancer patients was higher than expected. Some of the patients had a relatively good outcome.

This is a preview of subscription content, log in to check access.

Fig. 1
Fig. 2
Fig. 3

References

  1. 1.

    Honn KV, Aref A, Chen YQ et al (1996) Prostate cancer - old problems and new approaches. (Part II. Diagnostic and prognostic markers, Pathology and Biological Aspects). Pathol Oncol Res 2:191–211

    CAS  Article  Google Scholar 

  2. 2.

    Parimi V, Goyal R, Poropatich K, Yang XJ (2014) Neuroendocrine differenciation of prostate cancer: a review (2014). Am J Clin Exp Urol 2:273–285

    PubMed  PubMed Central  Google Scholar 

  3. 3.

    Li J, Wang Z (2016) The pathology of unusual subtypes of prostate cancer. Chin J Cancer Res 28:130–143

    CAS  PubMed  PubMed Central  Google Scholar 

  4. 4.

    Zaffuto E, Pompe R, Zanaty M et al (2017) Contemporary incidence and cancer control outcomes of primary neuroendocrine prostate cancer: a SEER database analysis. Clin Genitourin Cancer 15:e793–e800

    Article  Google Scholar 

  5. 5.

    Kishore K, Rafeeq A, Chime C et al (2018) Poorly differentiated small-cell-type neuroendocrine carcinoma of the prostate: a case report and literature review. Case Rep Oncol 11:676–681

    Article  Google Scholar 

  6. 6.

    Palmgren JS, Karavadia SS, Wakefield MR (2007) Unusual and underappreciated: small cell cancer of the prostate. Semin Oncol 34:22–29

    CAS  Article  Google Scholar 

  7. 7.

    Beltran H, Oromendia C, Danila DC et al (2019) A phase II trial of the Aurora kinase a inhibitor alisertib for patients with castration-resistant and neuroendocrine prostate cancer: efficacy and biomarkers. Clin Cancer Res 25:43–51

    Article  Google Scholar 

  8. 8.

    Monn MF, Cheng L (2016) Emerging trend in the evaluationand management of small cell prostate cancer: a clinical and molecular perspective. Expert Rev Anticancer Ther 16:1029–1037

    CAS  Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Tamás Kullmann.

Ethics declarations

Conflict of Interest

The authors have no conflict of interest in connection with the publication of this article.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Kránitz, N., Szepesváry, Z., Kocsis, K. et al. Neuroendocrine Cancer of the Prostate. Pathol. Oncol. Res. 26, 1447–1450 (2020). https://doi.org/10.1007/s12253-019-00712-2

Download citation

Keywords

  • Neuroendocrine
  • Prostate cancer
  • Immunohistochemistry
  • Serum marker
  • Platinum